ALBUQUERQUE, N.M.–(BUSINESS WIRE)–August 25, 2020–
WaveFront Dynamics Inc. (WaveDyn™), an early stage ophthalmic medical machine firm, right now introduced the primary shut of a $three million Series A financing spherical. The spherical was led by new investor Tramway Venture Partners LP and included investments from a Phoenix Venture Partners LP affiliate and a further angel investor. In reference to the financing, Waneta Tuttle of Tramway Venture Partners and Frank Levinson of Phoenix Venture Partners will be a part of WaveDyn’s Board of Directors. The funds will help continued improvement of its ophthalmic measurement machine with dynamic wavefront know-how and subsequent scientific research.
Founder and CEO of WaveDyn, Dan Neal, PhD, is an optical scientist with the imaginative and prescient to develop novel strategies to evaluate the visible efficiency of the human eye. The eye is repeatedly altering because it focuses on objects at numerous distances. WaveDyn is creating proprietary strategies to measure adjustments of the attention dynamically, over a sequence in time, moderately than a single snapshot. The firm will leverage its dynamic wavefront measurement capabilities to create ophthalmic remedy options for sufferers with advanced visible dysfunction.
“The dynamic wavefront guided treatment has the potential for improving the vision of hundreds of thousands of patients in the US alone,” stated Neal. “We’re happy to partner with lead investor Tramway Venture Partners, along with Phoenix Venture Partners’ affiliate, who have well-earned reputations working with early-stage startups. We look forward to working with this team of investors, who bring years of business and technical experience in support of our new venture.”
“We are excited to add WaveDyn to the Tramway portfolio,” stated Waneta Tuttle, Fund Manager for Tramway. “We were first attracted to the company by the experience of this talented team. We became increasingly interested in investing as we learned about the business plan and its approach to both diagnosing and correcting serious vision problems.”
“Dan and his team have already proven their ability to deliver ground-breaking ophthalmic instruments,” stated Frank Levinson, General Partner for Phoenix Venture Partners and its affiliate. “We’re excited to work along with the WaveDyn team. Their technology has the potential to bring unprecedented comfort and visual acuity for patients and lends itself to an attractive business model facilitated by a concentrated market access.”
Founded in 2019, WaveDyn is a privately held, early-stage medical machine firm with revolutionary wavefront diagnostic know-how to be used within the imaginative and prescient care trade. The firm plans to leverage the dynamic measurements to yield new insights into assessing visible efficiency, advancing remedy choices, and bettering high quality of life for the visually impaired. For extra data, please go to www.wavedyn.com.
About Tramway Venture Partners
Tramway Venture Partners is an early-stage enterprise fund investing in biotech, medtech, and healthtech. Typically, Tramway invests within the first institutional spherical after incubators and angel buyers. The greatest match with this technique is an organization led by an impressive administration workforce, that has a major mental property place, clear go to market methods, and a big addressable market. For extra data, please go to www.tramwayventurepartners.com.
About Phoenix Venture Partners’ affiliate
Phoenix Venture Partners (PVP) is a number one enterprise capital agency that invests in and companions with entrepreneurs to commercialize breakthrough supplies science improvements. PVP’s workforce has a observe document of founding, constructing and investing in profitable supplies science start-ups. PVP’s affiliate focuses on excessive potential, early stage firms. For extra data, please go to www.phoenix-vp.com.
Investor and Media Inquiries:
Dan Neal, PhD, Founder, CEO